Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Dollar change -0.05
Percentage change -1.14	%

Held by: VTI IWM VXF FESM IWO VTWO SCHA IWN IWC RSSL

Index	RUT	P/E	-	EPS (ttm)	-	Insider Own	41.29%	Shs Outstand	34.20M	Perf Week	-1.58%
Market Cap	155.94M	Forward P/E	-	EPS next Y	-4.70	Insider Trans	21.69%	Shs Float	21.05M	Perf Month	-1.58%
Income	-	PEG	-	EPS next Q	-1.90	Inst Own	31.08%	Short Float	8.81%	Perf Quarter	-78.35%
Sales	-	P/S	-	EPS this Y	-53.02%	Inst Trans	-6.59%	Short Ratio	3.67	Perf Half Y	-
Book/sh	9.17	P/B	0.47	EPS next Y	17.79%	ROA	-	Short Interest	1.85M	Perf Year	-
Cash/sh	9.33	P/C	0.47	EPS next 5Y	-	ROE	-	52W Range	3.85 - 26.62	Perf YTD	-24.87%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-83.66%	Beta	-
Dividend TTM	-	Quick Ratio	17.63	Sales past 5Y	0.00%	Gross Margin	-	52W Low	12.99%	ATR (14)	0.31
Dividend Ex-Date	-	Current Ratio	17.63	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	42.58	Volatility	5.61% 6.23%
Employees	-	Debt/Eq	0.03	Sales Y/Y TTM	-	Profit Margin	-	Recom	3.50	Target Price	6.33
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	-36.08%	Payout	-	Rel Volume	0.10	Prev Close	4.40
Sales Surprise	-	EPS Surprise	0.00%	Sales Q/Q	-	Earnings	Feb 26	Avg Volume	505.24K	Price	4.35
SMA20	-1.54%	SMA50	-9.23%	SMA200	-64.23%	Trades		Volume	20,825	Change	-1.14%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-28-25	Initiated	William Blair	Mkt Perform
Dec-10-24	Downgrade	Morgan Stanley	Overweight → Underweight	$40 → $5
Dec-09-24	Downgrade	Jefferies	Buy → Hold	$42 → $7
Dec-09-24	Downgrade	Citigroup	Buy → Neutral	$45 → $7
Oct-21-24	Initiated	Morgan Stanley	Overweight	$40
Oct-21-24	Initiated	Jefferies	Buy	$42
Oct-21-24	Initiated	Citigroup	Buy	$45

Mar-04-25 05:07AM	BioAge Labs (BIOA) Abandons Obesity Drug Amid Shareholder Lawsuit - Hagens Berman (Newsfile)
Feb-20-25 04:30PM	BioAge Labs to Participate in TD Cowen's 45th Annual Health Care Conference (GlobeNewswire)
10:36AM	BioAge Labs (BIOA) Abandons Obesity Drug Amid Shareholder Lawsuit - Hagens Berman (Newsfile)
Feb-16-25 07:18AM	BIOA COURT NEWS: BioAge Labs has been Sued for Securities Violations; Contact BFA Law by March 10 if You Lost Money (NASDAQ:BIOA) (GlobeNewswire)
Feb-14-25 05:45AM	Investors in BioAge Labs, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - BIOA (PR Newswire) +5.97%
08:42AM	Loading…
Feb-13-25 08:42AM	BioAge Labs (BIOA) Shares Plummet After Discontinuing Trial Just 2 Months After IPO- Hagens Berman (Newsfile)
Feb-07-25 05:45AM	BioAge Labs, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - BIOA (PR Newswire)
Jan-30-25 09:01AM	BioAge Labs (BIOA) Shares Plummet After Discontinuing Trial Just 2 Months After IPO- Hagens Berman (Newsfile)
Jan-29-25 05:39AM	BioAge drops obesity drug; Akero, 89bio cash in on MASH data (BioPharma Dive) -6.40%
Jan-28-25 07:27PM	Kessler Topaz Meltzer & Check, LLP Encourages BioAge Labs, Inc. Investors with Losses to Contact the Firm (PR Newswire)
09:00AM	BioAge Labs Announces Company Updates on APJ, NLRP3, and Platform Programs (GlobeNewswire)
Jan-24-25 05:45AM	Shareholders of BioAge Labs, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - BIOA (PR Newswire)
Jan-22-25 03:00AM	After an obesity stumble, BioAge reconnects with its longevity pipeline (Pharma Voice)
Jan-21-25 05:45AM	Investors in BioAge Labs, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - BIOA (PR Newswire)
Jan-18-25 03:07AM	BIOAGE LABS (BIOA) Investors are Notified the Company has been Sued and are Urged to Contact BFA Law by March 10 (Newsfile)
09:00PM	Loading…
Jan-06-25 09:00PM	Bragar Eagel and Squire, P.C. Is Investigating Franklin, MediaAlpha, e.l.f. Beauty, and BioAge and Encourages Investors to Contact the Firm (GlobeNewswire) -7.39%
Jan-03-25 12:51PM	BioAge Labs (BIOA) Shares Plummet After Discontinuing Trial Just 2 Months After IPO- Hagens Berman (PR Newswire)
Jan-02-25 09:35AM	BioAge Labs, Inc. (BIOA) Loses -67.99% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Jan-01-25 05:00AM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures - Hagens Berman (Newsfile)
Dec-27-24 11:32AM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures Hagens Berman (GlobeNewswire) -6.46%
09:18AM	BioAge Labs, Inc. (BIOA): A Bull Case Theory (Insider Monkey)
Dec-26-24 07:23AM	Kirby McInerney LLP is Investigating Potential Shareholder Claims Against BioAge Labs, Inc. (BIOA) (Newsfile)
Dec-25-24 07:04AM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures - Hagens Berman (Newsfile)
Dec-23-24 10:19AM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures Hagens Berman (GlobeNewswire)
Dec-19-24 01:15PM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures Hagens Berman (GlobeNewswire) +20.23%
05:46AM	BioAge and Novartis seek drug targets for ageing-related diseases (Pharmaceutical Technology)
Dec-18-24 09:00AM	BioAge Labs Announces Multi-Year Collaboration with Novartis to Discover Novel Targets for Therapies that Address Age-Related Diseases and Conditions (GlobeNewswire)
Dec-16-24 04:20PM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures Hagens Berman (GlobeNewswire)
03:00AM	3 closely watched drugs that failed in the clinic (Pharma Voice)
Dec-13-24 10:31AM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures - Hagens Berman (Newsfile) -6.75%
06:34PM	Loading…
Dec-12-24 06:34PM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures Hagens Berman (GlobeNewswire)
Dec-09-24 07:51PM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures Hagens Berman (GlobeNewswire) -76.85%
09:28AM	BioAge halts ongoing Phase II trial of obesity drug due to liver concerns (Clinical Trials Arena)
07:41AM	Just Two Months After IPO, BioAge Labs Stops Eli Lilly-Collaborated Obesity Trial On Safety Concerns (Benzinga)
Dec-07-24 06:34AM	BioAge shares tumble after decision to halt obesity drug study (BioPharma Dive)
Dec-06-24 04:35PM	BioAge Labs Announces Discontinuation of STRIDES Phase 2 Clinical Trial Evaluating Azelaprag in Combination with Tirzepatide for the Treatment of Obesity (GlobeNewswire) +9.36% -76.85%
Dec-05-24 04:30PM	BioAge Labs to Present at Goldman Sachs Year-Ahead Catalyst Clinic (GlobeNewswire)
Dec-04-24 04:47PM	Why BioAge Labs (BIOA) is the Best All-Time Low Stock to Buy Right Now? (Insider Monkey)
Nov-21-24 04:30PM	BioAge Labs to Present at Upcoming Investor Conferences (GlobeNewswire)
Nov-12-24 11:01PM	BioAge Labs Reports Strong Q3 2024 Achievements (TipRanks) -11.78%
Nov-07-24 04:30PM	BioAge Labs Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) -10.11% +7.61%
Nov-04-24 09:00AM	BioAge Labs to Present Preclinical Data for APJ Agonist Azelaprag at ObesityWeek 2024 (GlobeNewswire)
Oct-24-24 09:00AM	BioAge Labs to Present at Jefferies London Healthcare Conference (GlobeNewswire)
Oct-21-24 10:53AM	Wall Street analysts initiate coverage of BioAge Labs (Investing.com) +8.26%
Oct-17-24 09:45AM	Prediction: These 2 Stocks Could Soar in 2025 (Motley Fool)
Oct-12-24 02:31PM	Interested in Weight Loss Stocks Besides Novo Nordisk and Eli Lilly? You Might Want To Check Out This New IPO Stock (Motley Fool)
Oct-07-24 09:10PM	RA Capital Management, L.P. Acquires New Stake in Bioage Labs Inc (GuruFocus.com)
Oct-05-24 07:15AM	3 Reasons to Buy BioAge Labs Stock Hand Over Fist in October (Motley Fool)
Oct-03-24 09:05AM	This IPO Biotech Stock Could Be the Next Eli Lilly (Motley Fool) +5.73%
Oct-01-24 04:30PM	BioAge Labs Announces Closing of Initial Public Offering, Full Exercise of Underwriters' Option to Purchase Additional Shares and Closing of the Concurrent Private Placement (GlobeNewswire)
Sep-26-24 04:08PM	BioAge Labs, An Obesity Newcomer And Eli Lilly Partner, Rises On Upsized IPO (Investor's Business Daily)
02:36PM	A weight loss drug developer's stock soars after a $198 million IPO (Quartz)
08:25AM	BioAge Labs IPO: Stock price will be closely watched today as the obesity drug developer debuts on the Nasdaq (FastCompany)
Sep-25-24 08:00PM	BioAge Labs Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)
04:13PM	BioAge prices $198M IPO, validating pivot to obesity drug research (BioPharma Dive)
11:27AM	A weight loss drug maker is aiming for a big IPO (Quartz)

BioAge Labs, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapeutic products for metabolic diseases, such as obesity, by targeting the biology of human beings. It offers Azelaprag, a potential oral therapeutic for obesity, followed by several earlier-stage metabolic programs. The company was founded by Kristen Fortney and Eric Morgen on April 1, 2015 and is headquartered in Richmond, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Barton Shane	Principal Accounting Officer	Sep 27 '24	Buy	18.00	2,632	47,376	2,632	Mar 10 04:10 PM
Pande Vijay Satyanand	Director	Oct 01 '24	Buy	19.73	126,793	2,501,626	1,026,793	Oct 03 07:19 PM
Pande Vijay Satyanand	Director	Oct 02 '24	Buy	19.73	67,096	1,323,804	1,093,889	Oct 03 07:19 PM
Pande Vijay Satyanand	Director	Oct 03 '24	Buy	19.90	25,306	503,589	1,119,195	Oct 03 07:19 PM
Cormorant Asset Management, LP	Former 10% Owner	Sep 27 '24	Buy	18.00	450,000	8,100,000	1,629,529	Oct 01 04:01 PM
Pande Vijay Satyanand	Director	Sep 27 '24	Buy	18.00	900,000	16,200,000	900,000	Sep 27 04:28 PM
ENRIGHT PATRICK G	Director	Sep 27 '24	Buy	18.00	400,000	7,200,000	1,710,589	Sep 27 04:26 PM
HEALY JAMES	Director	Sep 27 '24	Buy	18.00	666,665	11,999,970	2,227,124	Sep 27 04:22 PM

Open in Screener

ALXO

Alx Oncology Holdings Inc

Mar 12 • 11:56AM ET

0.9313

Dollar change -0.0421
Percentage change -4.33	%

Healthcare • Biotechnology • USA • NASD

ALXO Alx Oncology Holdings Inc daily Stock Chart

Peers: IOVA KPTI SRRK XNCR CARA AFMD TGTX BHVN ZLAB BPMC

| Held by: VTI IWM VXF IWO VTWO SCHA VHT IWC VTWG ITOT

Index	RUT	P/E	-	EPS (ttm)	-2.61	Insider Own	36.24%	Shs Outstand	53.05M	Perf Week	-10.45%
Market Cap	49.71M	Forward P/E	-	EPS next Y	-1.42	Insider Trans	0.06%	Shs Float	34.04M	Perf Month	-10.45%
Income	-134.85M	PEG	-	EPS next Q	-0.52	Inst Own	56.29%	Short Float	17.29%	Perf Quarter	-42.51%
Sales	0.00M	P/S	-	EPS this Y	33.29%	Inst Trans	-3.34%	Short Ratio	4.59	Perf Half Y	-55.65%
Book/sh	2.14	P/B	0.43	EPS next Y	17.28%	ROA	-69.10%	Short Interest	5.89M	Perf Year	-93.88%
Cash/sh	2.39	P/C	0.39	EPS next 5Y	22.80%	ROE	-88.91%	52W Range	0.89 - 17.83	Perf YTD	-44.23%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-32.29%	ROI	-105.15%	52W High	-94.78%	Beta	1.02
Dividend TTM	-	Quick Ratio	7.26	Sales past 5Y	-35.07%	Gross Margin	-	52W Low	4.22%	ATR (14)	0.14
Dividend Ex-Date	-	Current Ratio	7.26	EPS Y/Y TTM	30.37%	Oper. Margin	-	RSI (14)	40.19	Volatility	21.44% 11.15%
Employees	80	Debt/Eq	0.15	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.57	Target Price	4.14
Option/Short	Yes / Yes	LT Debt/Eq	0.13	EPS Q/Q	40.49%	Payout	-	Rel Volume	0.62	Prev Close	0.97
Sales Surprise	-	EPS Surprise	17.91%	Sales Q/Q	-	Earnings	Mar 06 AMC	Avg Volume	1.28M	Price	0.93
SMA20	-13.16%	SMA50	-30.96%	SMA200	-69.81%	Trades		Volume	321,668	Change	-4.33%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-06-25	Upgrade	Jefferies	Hold → Buy	$2 → $3
Dec-19-24	Downgrade	Jefferies	Buy → Hold	$12 → $2
Mar-08-24	Downgrade	Stifel	Buy → Hold	$10 → $14
Dec-08-23	Upgrade	Jefferies	Hold → Buy	$8 → $18
Dec-22-21	Downgrade	Jefferies	Buy → Hold	$65 → $25
Sep-30-21	Initiated	Stifel	Buy	$106
May-05-21	Resumed	Credit Suisse	Outperform	$98
Apr-26-21	Resumed	Credit Suisse	Outperform	$98
Apr-06-21	Initiated	UBS	Buy
Feb-10-21	Initiated	H.C. Wainwright	Buy	$100
Aug-11-20	Initiated	Piper Sandler	Overweight	$55
Aug-11-20	Initiated	Jefferies	Buy	$50
Aug-11-20	Initiated	Credit Suisse	Outperform	$53
Aug-11-20	Initiated	Cantor Fitzgerald	Overweight	$64

Show Previous Ratings

Mar-08-25 07:33AM	Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge (PR Newswire)
Mar-07-25 01:27PM	Why ALX Oncology Holdings Inc. (ALXO) Soared on Thursday (Insider Monkey) -19.08%
Mar-06-25 04:01PM	ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire) +25.96%
Mar-05-25 08:00AM	ALX Oncology Highlights Focused Evorpacept Development Plan, Clinical Progress and Corporate Updates at R&D Day Webcast Event (GlobeNewswire)
Feb-27-25 08:00AM	ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025 (GlobeNewswire)
08:00AM	Loading…
Feb-18-25 08:00AM	ALX Oncology to Host Virtual R&D Day on March 5, 2025 (GlobeNewswire) +7.27%
Jan-23-25 02:44PM	ALX Oncology Shares Drop 15% Following Positive Phase 2 (GuruFocus.com) -9.44%
08:00AM	ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer (GlobeNewswire)
Jan-22-25 04:01PM	ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules (GlobeNewswire) +9.09%
09:00AM	Oncology's Best Minds Set to Meet at Upcoming 2025 ASCO Gastrointestinal Cancers Symposium (PR Newswire)
08:00AM	ALX Oncology Announces Further Additions to Leadership Team and Board of Directors, Appointing Harish Shantharam as Chief Financial Officer and Adding Barbara Klencke and Chris Takimoto to Board of Directors (GlobeNewswire)
Jan-21-25 05:00PM	ALX Oncology to Host Virtual Company Event Highlighting Updated Data from ASPEN-06 Phase 2 Trial Presented at 2025 ASCO GI (GlobeNewswire) -5.17%
Jan-07-25 09:40AM	Is ALX Oncology Holdings (ALXO) Outperforming Other Medical Stocks This Year? (Zacks)
08:00AM	ALX Oncology to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-19-24 08:57AM	Alx Oncology shares down in pre-market as Jefferies downgrades stock to 'hold' (Investing.com) -19.57%
08:00AM	Loading…
Dec-18-24 08:00AM	ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium (GlobeNewswire)
Dec-12-24 08:00AM	ALX Oncology to Host Virtual Company Event Highlighting New Clinical Data Presented at SABCS 2024 (GlobeNewswire) -5.96%
Dec-10-24 09:00AM	ALX Oncology Announces New Data Demonstrating Evorpacept in Combination with Zanidatamab Generates Promising Antitumor Activity in Advanced Breast Cancer (GlobeNewswire) -8.14%
Nov-26-24 08:00AM	ALX Oncology to Participate in the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire)
Nov-21-24 09:35AM	ALX Oncology Holdings (ALXO) Loses -27.11% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) +6.61%
Nov-14-24 08:00AM	ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer (GlobeNewswire)
Nov-07-24 04:00PM	ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-04-24 08:00AM	ALX Oncology Announces November Investor Conference Participation (GlobeNewswire)
Nov-01-24 05:30PM	ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024 (GlobeNewswire)
Oct-10-24 07:04PM	Millennium Management LLC Reduces Stake in ALX Oncology Holdings Inc (GuruFocus.com) -11.11% +6.94%
Sep-09-24 08:00AM	ALX Oncology to Present at the 2024 Cantor Fitzgerald Global Healthcare Conference (GlobeNewswire) +9.95%
Sep-04-24 08:00AM	ALX Oncology Announces First Patients Dosed with Evorpacept and Sarclisa As Part of Randomized Phase 1/2 UMBRELLA Study with Sanofi (GlobeNewswire)
Aug-08-24 04:05PM	ALX Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-06-24 04:01PM	ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors (GlobeNewswire) -6.55%
Aug-01-24 09:05AM	Immuno-Oncology Focused ALX Oncology Stock Falls On Updated Data From Mid-Stage Evorpacept Combo Study In Gastric Cancer Patients (Benzinga) -41.67%
06:52AM	Loading…
06:52AM	ALX Oncologys evorpacept shows potential in Phase II gastric cancer trial (Clinical Trials Arena)
Jul-31-24 04:01PM	ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer (GlobeNewswire) -11.93%
05:30AM	ALX Oncology to Host Investor Call and Webcast to Share Topline Data Results From ASPEN-06 Phase 2 Clinical Trial of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer (GlobeNewswire)
Jun-17-24 11:00AM	Insider Buying: CFO Peter Garcia Acquires Shares of ALX Oncology Holdings Inc (ALXO) (GuruFocus.com) -8.32%
Jun-03-24 09:35AM	Down -30.79% in 4 Weeks, Here's Why ALX Oncology Holdings (ALXO) Looks Ripe for a Turnaround (Zacks) -15.71%
Jun-02-24 10:00AM	ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer (GlobeNewswire)
May-29-24 09:00AM	ALX Oncology Announces Participation in the Jefferies Global Healthcare Conference (GlobeNewswire) -10.91%
May-16-24 02:54AM	Insider Sale: Chief Medical Officer of ALX Oncology Holdings Inc (ALXO) Sells Shares (GuruFocus.com)
May-14-24 09:55AM	Wall Street Analysts Think ALX Oncology Holdings (ALXO) Could Surge 36.64%: Read This Before Placing a Bet (Zacks)
May-10-24 02:21PM	ALX Oncology Holdings Inc (ALXO) Q1 2024 Earnings Analysis: A Detailed Look at Financials and ... (GuruFocus.com)
May-09-24 10:57PM	ALXO Stock Earnings: ALX Oncology Holdings Beats EPS for Q1 2024 (InvestorPlace)
04:00PM	ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
May-08-24 05:38PM	Alx Oncology Holdings Insider Sold Shares Worth $318,334, According to a Recent SEC Filing (MT Newswires) -5.41%
May-07-24 09:00AM	ALX Oncology Appoints Allison Dillon as Chief Business Officer (GlobeNewswire) +11.28%
Apr-30-24 09:00AM	ALX Oncology Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination with Pembrolizumab in Patients with Untreated HPV-Mediated Oropharyngeal Cancer (GlobeNewswire)
Apr-24-24 10:00AM	ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting (GlobeNewswire)
Apr-11-24 09:30AM	ALX Oncology (ALXO) Posts Upbeat Results From Lymphoma Study (Zacks) +11.04%
Apr-09-24 05:30PM	ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma ( R/R B-NHL ) (GlobeNewswire)
Apr-06-24 01:33AM	ALX Oncology Holdings Inc (ALXO) Insider Sells Shares (GuruFocus.com)
Mar-08-24 03:48PM	ALX Oncology Has 'Elevated Valuation' - Analyst Downgrades Stock, Highlights Need For Development De-Risking Beyond Gastric Cancer (Benzinga) -6.34%
Mar-07-24 10:53PM	ALXO Stock Earnings: ALX Oncology Holdings Beats EPS for Q4 2023 (InvestorPlace) +9.95%
10:41PM	ALX Oncology Holdings Inc (ALXO) Reports Growth Amidst Increased R&D Spending (GuruFocus.com)
04:03PM	ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-05-24 04:30PM	ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting (GlobeNewswire)
Jan-03-24 08:00AM	ALX Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-22-23 04:21PM	7 Small-Cap Stocks That Wall Street Loves for Good Reason (InvestorPlace) +18.04%
Nov-13-23 04:47PM	ALX Oncology Holdings Inc (ALXO) Reports Q3 2023 Financial Results and Corporate Developments (GuruFocus.com) +8.08%
04:05PM	ALX Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-01-23 04:05PM	ALX Oncology Announces November Investor Conference Participation (GlobeNewswire) +6.35%
Oct-10-23 04:05PM	ALX Oncology Announces Closing of Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) +16.24%
Oct-06-23 04:59AM	The Zacks Analyst Blog Highlights Novavax, ALX Oncology, Regeneron Pharmaceuticals, Intellia and Moderna (Zacks) +27.38%
Oct-05-23 10:58AM	Biotech Stock Roundup: NVAX Up on Updates, ALXO Gains on Study Data & More (Zacks)
08:00AM	ALX Oncology Announces Pricing of Public Offering (GlobeNewswire)
Oct-04-23 04:10PM	ALX Oncology Announces Proposed Public Offering (GlobeNewswire) -15.05%
11:39AM	ALX Oncology (ALXO) Up 56% on Upbeat Gastric Cancer Study Data (Zacks)
Oct-03-23 11:15AM	Why ALX Oncology Stock Is Skyrocketing Today (Motley Fool) +56.13%
09:36AM	Midday movers: McCormick Airbnb, Point Biopharma and more (Investing.com)
06:00AM	ALX Oncology Reports Positive Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer (GlobeNewswire)
Oct-02-23 04:05PM	ALX Oncology to Host Investor Call and Webcast on October 3, 2023 to Share Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer (GlobeNewswire)
Sep-06-23 08:00AM	ALX Oncology Realigns Executive Leadership Team (GlobeNewswire) +6.37%
Aug-31-23 07:00AM	ALX Oncology Announces September Investor Conference Participation (GlobeNewswire)
Aug-14-23 07:31PM	While dollars continue to flow into biotech, companies cut more jobs (American City Business Journals)
Aug-10-23 04:01PM	ALX Oncology Reports Second Quarter 2023 Financial Results and Provides Clinical Program Update (GlobeNewswire)
09:55AM	ALX Oncology Holdings Inc. (ALXO) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks)
Jun-26-23 07:00AM	ALX Oncology Receives Orphan Drug Designation from the European Commission for Evorpacept for the Treatment of Patients with Gastric Cancer (GlobeNewswire)
May-11-23 04:01PM	ALX Oncology Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights (GlobeNewswire)
May-09-23 07:00AM	ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of Evorpacept in Patients with Ovarian Cancer (GlobeNewswire) +6.36%
Apr-25-23 07:00AM	ALX Oncology Announces Clinical Trial Collaboration with Sanofi to Evaluate Evorpacept in Combination with SARCLISA (isatuximab-irfc) in Patients with Multiple Myeloma (GlobeNewswire)
Apr-19-23 11:36AM	These 2 Strong Buy Penny Stocks Could Rally to $40 (or More), Says Piper Sandler (TipRanks) +6.44%
Mar-14-23 08:00AM	ALX Oncology and Quantum Leap Healthcare CollaborativeTM Announce First Patient Dosed in the I-SPY-P1 TRIAL in Breast Cancer (PR Newswire) -6.75%
Mar-13-23 07:00AM	ALX Oncology and Quantum Leap Healthcare Collaborative Announce First Patient Dosed in the I-SPY-P1 TRIAL in Breast Cancer (GlobeNewswire)
Mar-09-23 04:01PM	ALX Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights and Upcoming Milestones (GlobeNewswire) -5.93% -8.18%
Feb-16-23 07:00AM	ALX Oncology Announces First Patient Dosed in ASPEN-07, a Phase 1 Study of Evorpacept for the Treatment of Patients with Urothelial Cancer (GlobeNewswire)
Jan-05-23 07:00AM	ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2023 (GlobeNewswire)
Jan-03-23 07:00AM	ALX Oncology to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-12-22 10:00AM	ALX Oncology Announces Initial Data from ASPEN-05 Study of Evorpacept in Combination with Azacitidine and Venetoclax, Demonstrating Tolerability and Preliminary Activity in Patients with Acute Myeloid Leukemia (GlobeNewswire) +5.12%
Nov-29-22 07:00AM	ALX Oncology Appoints Scott Garland to its Board of Directors (GlobeNewswire) +7.25%
Nov-08-22 04:01PM	ALX Oncology Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights (GlobeNewswire)
Nov-03-22 09:00AM	ALX Oncology to Present New Clinical Data on Evorpacept in Acute Myeloid Leukemia at 64th ASH Annual Meeting (GlobeNewswire)
Nov-02-22 07:00AM	ALX Oncology Announces Upcoming Investor Conference Participation (GlobeNewswire)
Oct-31-22 07:00AM	ALX Oncology Enters $100 Million Loan Facility Agreement with Oxford Finance and Silicon Valley Bank to Support Ongoing Development of Evorpacept (GlobeNewswire)
Oct-05-22 08:01AM	ALX Oncology Announces Trials in Progress Abstracts Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting (GlobeNewswire)
Sep-21-22 04:01PM	ALX Oncology to Participate in the Cantor Oncology, Hematology & HemeOnc Conference (GlobeNewswire)
Sep-01-22 07:00AM	ALX Oncology Announces Upcoming Investor Conference Participation (GlobeNewswire)
Aug-16-22 09:45AM	ALX Oncology and Quantum Leap Healthcare Collaborative Announce the Selection of Evorpacept in the I-SPY-P1 TRIAL in Combination with Enhertu® in Breast Cancer (PR Newswire)
Aug-15-22 07:00AM	ALX Oncology and Quantum Leap Healthcare Collaborative Announce the Selection of Evorpacept in the I-SPY-P1 TRIAL in Combination with Enhertu® in Breast Cancer (GlobeNewswire)
Aug-11-22 07:00AM	ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of Evorpacept in Combination with Cetuximab and Pembrolizumab in Patients with Advanced Colorectal Cancer (GlobeNewswire)
Aug-08-22 04:01PM	ALX Oncology Reports Second Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights (GlobeNewswire)
Aug-01-22 07:00AM	ALX Oncologys Evorpacept Receives Fast Track Designation from FDA as First-Line Treatment for Head and Neck Squamous Cell Carcinoma (GlobeNewswire)
Jun-29-22 08:44AM	ALX's stock is up 11% after getting orphan-drug designation for cancer drug (MarketWatch)

ALX Oncology Holdings, Inc. operates as a clinical stage company, which engages in the research and development of therapies for cancer patients. Its objective is to provide clinical therapies for the treatment of myelodysplastic syndromes, acute myeloid leukemia, and a range of solid tumor indications. The company was founded by Corey Goodman, Jaume Pons, and K. Christopher Garcia in March 2015 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Pinto Shelly	SVP, FINANCE AND CAO	Feb 19 '25	Sale	1.15	550	633	87,352	Feb 21 04:25 PM
Pons Jaume	PRESIDENT & CSO	Feb 19 '25	Sale	1.15	1,326	1,525	579,388	Feb 21 04:23 PM
Lettmann Jason	CHIEF EXECUTIVE OFFICER	Feb 19 '25	Sale	1.15	2,159	2,483	170,270	Feb 21 04:20 PM
Pinto Shelly	Interim CFO	Jan 06 '25	Sale	1.80	2,221	3,998	87,902	Jan 08 04:10 PM
Pinto Shelly	Interim CFO	Dec 30 '24	Sale	1.58	1,426	2,253	90,123	Jan 02 04:46 PM
Pons Jaume	PRESIDENT & CSO	Dec 30 '24	Sale	1.58	10,796	17,060	580,714	Jan 02 04:43 PM
Hemrajani Rekha	Director	Dec 02 '24	Buy	1.55	30,000	46,404	33,000	Dec 04 04:17 PM
Pinto Shelly	SVP, FINANCE AND CAO	Aug 14 '24	Sale	2.58	564	1,455	91,549	Aug 16 05:10 PM
Randolph Sophia	CHIEF MEDICAL OFFICER	Aug 14 '24	Sale	2.58	1,365	3,522	325,711	Aug 16 05:09 PM
Pons Jaume	PRESIDENT & CSO	Aug 14 '24	Sale	2.58	1,937	4,997	591,510	Aug 16 05:06 PM
Pons Jaume	PRESIDENT & CSO	Jul 11 '24	Option Exercise	0.99	20,000	19,800	613,447	Jul 15 04:06 PM
Pons Jaume	PRESIDENT & CSO	Jul 11 '24	Sale	7.90	20,000	158,076	593,447	Jul 15 04:06 PM
Pinto Shelly	SVP, FINANCE AND CAO	Jul 05 '24	Sale	5.50	1,823	10,025	92,113	Jul 09 04:09 PM
Pinto Shelly	SVP, FINANCE AND CAO	Jul 01 '24	Sale	5.82	1,373	7,989	93,936	Jul 03 05:03 PM
Randolph Sophia	CHIEF MEDICAL OFFICER	Jul 01 '24	Sale	5.82	3,273	19,045	327,076	Jul 03 05:02 PM
Pons Jaume	PRESIDENT & CSO	Jul 01 '24	Sale	5.82	10,758	62,599	593,447	Jul 03 05:00 PM
GARCIA PETER S	CHIEF FINANCIAL OFFICER	Jun 13 '24	Buy	8.53	12,000	102,338	122,348	Jun 17 07:29 AM
Pons Jaume	PRESIDENT & CSO	Jun 04 '24	Option Exercise	0.99	20,000	19,800	624,205	Jun 06 04:06 PM
Pons Jaume	PRESIDENT & CSO	Jun 04 '24	Sale	8.43	20,000	168,652	604,205	Jun 06 04:06 PM
Randolph Sophia	CHIEF MEDICAL OFFICER	May 13 '24	Sale	15.94	12,000	191,339	330,349	May 15 04:30 PM
Pons Jaume	PRESIDENT & CSO	May 06 '24	Option Exercise	0.99	20,000	19,800	624,205	May 08 05:31 PM
Pons Jaume	PRESIDENT & CSO	May 06 '24	Sale	15.92	20,000	318,334	604,205	May 08 05:31 PM
Pons Jaume	PRESIDENT & CSO	Apr 16 '24	Option Exercise	0.99	25,846	25,588	654,205	Apr 18 04:49 PM
Pons Jaume	PRESIDENT & CSO	Apr 16 '24	Sale	14.20	50,000	710,195	604,205	Apr 18 04:49 PM
Pons Jaume	PRESIDENT & CSO	Apr 04 '24	Sale	11.15	20,000	223,036	628,359	Apr 05 05:37 PM
Lettmann Jason	CHIEF EXECUTIVE OFFICER	Mar 14 '24	Buy	11.31	4,400	49,771	171,620	Mar 18 04:06 PM

BIOA

BioAge Labs Inc

ALXO

Alx Oncology Holdings Inc

Upgrade your FINVIZ experience